Maintenance Pembrolizumab Did Not Improve PFS in Small-Cell Lung Cancer

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

This video examines a phase II trial that studied maintenance pembrolizumab in extensive-stage small-cell lung cancer.

In this video, Shirish M. Gadgeel, MD, of the University of Michigan, discusses a phase II trial that studied pembrolizumab in the maintenance setting for the treatment of extensive-stage small-cell lung cancer patients.

Gadgeel presented results of the study (abstract 8504) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.

Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Related Content
AI, Immunotherapy, More Key Lung Cancer Advances Highlighted at 2025 ELCC

AI, Immunotherapy, More Key Lung Cancer Advances Highlighted at 2025 ELCC

Ariana Pelosci
April 1st 2025
Article

An expert panel at ELCC 2025 reviews the MARIPOSA trial's implications for first-line therapy in EGFR-mutated NSCLC and broader advancements.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Patients with driver gene–negative non–small cell lung cancer who received immunotherapy beyond progression experienced better survival outcomes.

Continuous Second-Line Immunotherapy May Benefit Pretreated Lung Cancer

Roman Fabbricatore
March 6th 2025
Article

Patients with driver gene–negative non–small cell lung cancer who received immunotherapy beyond progression experienced better survival outcomes.

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

Neil M. Iyengar, MD;Paolo Tarantino, MD
June 17th 2024
Podcast

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Lung cancer

Deep Learning Models Expedite Biomarker Discovery, Detection in Lung Cancer

Silas Inman
September 7th 2024
Article

Investigators showcased feasibility of combining pathology findings with deep learning artificial intelligence to speed up biomarker detection and discovery for patients with lung cancer.

The mean number of palliative care visits was nearly halved for stepped-palliative care vs early palliative care in patients with advanced lung cancer.

Stepped Care Model for Lung Cancer May Maintain QOL With Fewer Visits

Roman Fabbricatore
August 6th 2024
Article

The mean number of palliative care visits was nearly halved for stepped-palliative care vs early palliative care in patients with advanced lung cancer.